This editorial summarizes recent advances in pharmacogenetics of solid cancers, emphasizing how genetic variability shapes drug response and supports personalized therapies. Contributions highlight RNA sequencing for oncogenic fusions, CYP polymorphisms affecting mitotane metabolism, RET gene–targeted treatments, computational tools for pharmacogenomic profiling, and gene signatures for renal cancer stratification—showcasing the clinical potential of pharmacogenomics in oncology.
Editorial: Pharmacogenetic landscape in human solid cancers
Colombo F.Writing – Review & Editing
;
2023
Abstract
This editorial summarizes recent advances in pharmacogenetics of solid cancers, emphasizing how genetic variability shapes drug response and supports personalized therapies. Contributions highlight RNA sequencing for oncogenic fusions, CYP polymorphisms affecting mitotane metabolism, RET gene–targeted treatments, computational tools for pharmacogenomic profiling, and gene signatures for renal cancer stratification—showcasing the clinical potential of pharmacogenomics in oncology.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
fonc-13-1343395_editorial_Frontiers.pdf
non disponibili
Licenza:
Creative commons
Dimensione
236.19 kB
Formato
Adobe PDF
|
236.19 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
